Table 1 Demographic data and biomarker CSF levels for the diagnostic groups^a

 Number (men/women)

17 (7/10)

5 (1/4)

17 (5/12)

 Age (years)

60 (53–67), P = 0.02^c

78 (73–81), P = 0.02^b

65 (58–81)

 MMSE

27 (24–28)

27 (27–28)

21 (16–23), P = 0.00001^b, P = 0.004^c

 Amyloid-β_1–42 (ng/L)

838 (697–998), P = 0.001^c

539 (316–582), P = 0.001^b

398 (319–483), P < 0.00001^b

 Total tau (ng/L)

180 (126–206), P = 0.00008^c

1000 (766–1078), P = 0.00008^b

602 (442–769), P < 0.00001^b

 Phosphorylated tau (ng/L)

39 (35–42), P = 0.00008^c

143 (97–180), P = 0.00008^b

89 (75–119), P < 0.00001^b

 Number (men/women)

36 (13/23)

18 (5/13)

24 (7/17)

 Age (years)

62 (55–69), P = 0.001^c

70 (69–78), P = 0.001^b

68 (64–72), P = 0.02^b

 MMSE

28 (26–29)

27 (26–28)

22 (17–24), P = 0.00001^b, P = 0.00001^c

 Amyloid-β_1–42 (ng/L)

971 (844–1110), P < 0.00001^c

558 (377–667), P < 0.00001^b

497 (459–571), P < 0.00001^b

 Total tau (ng/L)

197 (157–227), P < 0.00001^c

570 (520–717), P < 0.00001^b

623 (527–799), P < 0.00001^b

 Phosphorylated tau (ng/L)

40 (32–46), P < 0.00001^c

86 (79–104), P < 0.00001^b

91 (73–115), P < 0.00001^b